CL2014003144A1 - Uso de mesalamina granulada para el tratamiento de un trastorno gastrointestinal tal como enfermedad del intestino irritable, enfermedad de crohn, colitis ulcerosa y gastroparesia, que comprende administrar dicha mesalamina granulada a un sujeto, el cual tiene un nivel de proteina c reactiva de al menos 2,2 mg/l. - Google Patents
Uso de mesalamina granulada para el tratamiento de un trastorno gastrointestinal tal como enfermedad del intestino irritable, enfermedad de crohn, colitis ulcerosa y gastroparesia, que comprende administrar dicha mesalamina granulada a un sujeto, el cual tiene un nivel de proteina c reactiva de al menos 2,2 mg/l.Info
- Publication number
- CL2014003144A1 CL2014003144A1 CL2014003144A CL2014003144A CL2014003144A1 CL 2014003144 A1 CL2014003144 A1 CL 2014003144A1 CL 2014003144 A CL2014003144 A CL 2014003144A CL 2014003144 A CL2014003144 A CL 2014003144A CL 2014003144 A1 CL2014003144 A1 CL 2014003144A1
- Authority
- CL
- Chile
- Prior art keywords
- granulated mesalamine
- disease
- gastroparesis
- crohn
- subject
- Prior art date
Links
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 title 2
- 229960004963 mesalazine Drugs 0.000 title 2
- 206010009900 Colitis ulcerative Diseases 0.000 title 1
- 208000011231 Crohn disease Diseases 0.000 title 1
- 208000018522 Gastrointestinal disease Diseases 0.000 title 1
- 206010021518 Impaired gastric emptying Diseases 0.000 title 1
- 201000006704 Ulcerative Colitis Diseases 0.000 title 1
- 208000010643 digestive system disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000018685 gastrointestinal system disease Diseases 0.000 title 1
- 208000001288 gastroparesis Diseases 0.000 title 1
- 208000002551 irritable bowel syndrome Diseases 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261649268P | 2012-05-19 | 2012-05-19 | |
US201261682154P | 2012-08-10 | 2012-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014003144A1 true CL2014003144A1 (es) | 2015-07-17 |
Family
ID=49621801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014003144A CL2014003144A1 (es) | 2012-05-19 | 2014-11-19 | Uso de mesalamina granulada para el tratamiento de un trastorno gastrointestinal tal como enfermedad del intestino irritable, enfermedad de crohn, colitis ulcerosa y gastroparesia, que comprende administrar dicha mesalamina granulada a un sujeto, el cual tiene un nivel de proteina c reactiva de al menos 2,2 mg/l. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20130316000A1 (es) |
EP (1) | EP2849565A4 (es) |
JP (1) | JP2015517521A (es) |
CN (1) | CN104394691A (es) |
AU (1) | AU2013266857B2 (es) |
CA (1) | CA2873855A1 (es) |
CL (1) | CL2014003144A1 (es) |
EA (1) | EA201401286A1 (es) |
IL (1) | IL235640A0 (es) |
MX (1) | MX2014013719A (es) |
NZ (1) | NZ702643A (es) |
WO (1) | WO2013176763A1 (es) |
ZA (1) | ZA201407975B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140141075A1 (en) | 2012-11-21 | 2014-05-22 | Warner Chilcott Company, Llc | 5-aminosalicylic acid capsule formulation |
JP2017515896A (ja) * | 2014-05-09 | 2017-06-15 | ノグラ ファーマ リミテッド | 炎症性腸疾患の処置の方法 |
CN110038017A (zh) * | 2018-01-16 | 2019-07-23 | 重庆医科大学 | 5-氨基水杨酸的新用途 |
CN111905111B (zh) * | 2020-09-16 | 2023-03-31 | 地奥集团成都药业股份有限公司 | 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法 |
WO2023102491A1 (en) * | 2021-12-01 | 2023-06-08 | Invea Therapeutics, Inc. | Methods for treating gastrointestinal inflammatory disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992016214A1 (en) * | 1991-03-15 | 1992-10-01 | Norwich Eaton Pharmaceuticals Inc. | The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d) |
WO2008085484A2 (en) * | 2006-12-28 | 2008-07-17 | Jacobus Pharmaceutical Company, Inc. | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid |
CN102238868A (zh) * | 2008-10-03 | 2011-11-09 | 福尔克博士药物有限责任公司 | 使用颗粒状5-氨基水杨酸治疗肠病的组合物和方法 |
KR20120101038A (ko) * | 2009-10-30 | 2012-09-12 | 프로메테우스 레버러터리스 인코포레이티드 | 과민성대장증후군을 진단하는 방법 |
-
2013
- 2013-03-15 CA CA2873855A patent/CA2873855A1/en not_active Abandoned
- 2013-03-15 MX MX2014013719A patent/MX2014013719A/es unknown
- 2013-03-15 EP EP13794066.4A patent/EP2849565A4/en not_active Withdrawn
- 2013-03-15 NZ NZ702643A patent/NZ702643A/en not_active IP Right Cessation
- 2013-03-15 US US13/832,440 patent/US20130316000A1/en not_active Abandoned
- 2013-03-15 JP JP2015512648A patent/JP2015517521A/ja active Pending
- 2013-03-15 WO PCT/US2013/031848 patent/WO2013176763A1/en active Application Filing
- 2013-03-15 CN CN201380033349.9A patent/CN104394691A/zh active Pending
- 2013-03-15 AU AU2013266857A patent/AU2013266857B2/en not_active Ceased
- 2013-03-15 EA EA201401286A patent/EA201401286A1/ru unknown
-
2014
- 2014-10-31 ZA ZA2014/07975A patent/ZA201407975B/en unknown
- 2014-11-11 IL IL235640A patent/IL235640A0/en unknown
- 2014-11-19 CL CL2014003144A patent/CL2014003144A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN104394691A (zh) | 2015-03-04 |
MX2014013719A (es) | 2015-02-10 |
EA201401286A1 (ru) | 2015-04-30 |
NZ702643A (en) | 2016-06-24 |
AU2013266857B2 (en) | 2016-02-11 |
WO2013176763A1 (en) | 2013-11-28 |
US20130316000A1 (en) | 2013-11-28 |
AU2013266857A1 (en) | 2015-01-15 |
EP2849565A4 (en) | 2016-03-23 |
JP2015517521A (ja) | 2015-06-22 |
IL235640A0 (en) | 2015-02-01 |
CA2873855A1 (en) | 2013-11-28 |
ZA201407975B (en) | 2015-11-25 |
EP2849565A1 (en) | 2015-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015001250A1 (es) | Compuestos derivados de triazolopirazinas, inhibidores de brd4; preparacion farmaceutica; y su uso en el tratamiento y/o la prevencion de cancer, tal como cancer de pulmon, higado, colon, cerebro, tiroides, mamas, entre otros. | |
CL2014000343A1 (es) | Procedimientos de preparacion de compuesto polimorfico derivado de pirazolo[3,4-d]pirimidina; sal del compuesto; composicion farmaceutica que lo comprende y su uso en el tratamiento de un trastorno asociado a mtor. | |
ECSP14017584A (es) | Compuestos inhibidores de raf | |
CL2015001785A1 (es) | Compuestos derivados de heterociclos nitrogenados, moduladores de quinasas; metodo de preparacion; compuesto iintermediario; composicion farmaceutica; y un metodo para tratar un sujeto que posee una enferemedad o condicion como cancer, aml, tumores estromales gastrointestinales o mastocitosis. | |
CL2013002125A1 (es) | Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia. | |
EA032986B1 (ru) | Пирролобензодиазепины | |
DOP2014000170A (es) | Compuestos de imidazopirrolidinona | |
CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
CL2015000615A1 (es) | Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau. | |
BR112015003376A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente | |
CL2014003171A1 (es) | Composicion liofilizada que comprende al menos una benzodiazepina de formula (i), al menos un excipiente higroscopico seleccionado de disacaridos y dextrano; metodo de preparacion de la composicion farmaceutica. | |
CL2014003144A1 (es) | Uso de mesalamina granulada para el tratamiento de un trastorno gastrointestinal tal como enfermedad del intestino irritable, enfermedad de crohn, colitis ulcerosa y gastroparesia, que comprende administrar dicha mesalamina granulada a un sujeto, el cual tiene un nivel de proteina c reactiva de al menos 2,2 mg/l. | |
BR112012002124A2 (pt) | tratamento da doença de crohn com laquinimode. | |
CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. | |
LT2844279T (lt) | Dozavimo režimai, skirti pompe ligos gydymui | |
BR112015003259A2 (pt) | composto, composição farmacêutica, e, composição de vacina. | |
CL2014003429A1 (es) | Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia. | |
MX2015005948A (es) | Polipeptidos para transporte de barrera hematoencefalica. | |
AP2014007399A0 (en) | Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament | |
CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
BR112014025041B8 (pt) | Composição farmacêutica | |
CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
CL2015001610A1 (es) | Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende. | |
EA201591698A1 (ru) | Макроциклические ингибиторы киназы lrrk2 | |
IL248592A0 (en) | Treatment of Crohn's disease using delayed-release 6-mercaptofurin |